Drug intelligence / Profile preview

5-aminolevulinic acid + carmustine

Development stage: Unknown
Lead developer: Specialised
Modality: Small Molecules
Administration: Oral, Implant

Overview

A combination therapy consisting of 5-aminolevulinic acid (5-ALA) and carmustine. 5-ALA is a porphyrin precursor that leads to selective accumulation of fluorescent compounds in tumor tissue, enabling better visualization during surgery. Carmustine is an alkylating agent that causes cross-links in DNA and RNA, inhibiting cellular processes and leading to cell death. This combination is primarily investigated for the treatment of glioblastoma, with 5-ALA used for fluorescence-guided resection and carmustine wafers implanted during surgery for local chemotherapy delivery.

Other names: 5-ALA + carmustineGliolan + Gliadel

Targets

Heme biosynthetic pathwayDNAGSR (Glutathione reductase)

Beyond the preview

Go deeper on 5-aminolevulinic acid + carmustine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-aminolevulinic acid + carmustine.

Explore the full profile